Last reviewed · How we verify
nevirapine, stavudine, lamivudine
At a glance
| Generic name | nevirapine, stavudine, lamivudine |
|---|---|
| Sponsor | Makerere University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- A Prospective Cohort of Children With HIV Infection
- Preventing Sexual Transmission of HIV With Anti-HIV Drugs (PHASE3)
- Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children (PHASE2, PHASE3)
- Treatment With Combinations of Several Antiviral Drugs in Infants and Young Children With HIV Infection (PHASE2)
- Safety and Effectiveness of Four Anti-HIV Drug Combinations in HIV-Infected Children and Teens (PHASE1)
- Comparison of New Anti-HIV Drug Combinations in HIV-Infected Children Who Have Taken Anti-HIV Drugs (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- nevirapine, stavudine, lamivudine CI brief — competitive landscape report
- nevirapine, stavudine, lamivudine updates RSS · CI watch RSS
- Makerere University portfolio CI